Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Alzheimer’s Disease Market $25 Billion by 2027

The global market for Alzheimer’s disease expected to attain $25 billion by 2027, growing at a staggering CAGR of 17.5% over the forecast period, driven by rapidly ageing population, increasing prevalence of AD, coupled with technological advancements in diagnostics and biomarkers.

Global Alzheimer’s Disease Market

Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80% of cases in the US, Japan and five major EU markets (the UK, Germany, France, Italy, and Spain).

  • According to Alzheimer’s Association, in 2018, an estimated 5.7 million people in the United States who are aged 65 or older are living with AD. By 2050, this number is predicted to increase to approximately 14 million.
  • According to the World Health Organization, an estimated 50 million people worldwide currently have dementia, and there are nearly 10 million new cases every year; Alzheimer disease affects about 60-70% of them.

Alzheimer’s disease is the sixth-leading cause of death in the United States, and the fifth-leading cause of death among those age 65 and older. It also is a leading cause of disability and poor health. There are a large number of patients at the earliest stages of disease, before the onset of dementia, currently undiagnosed and untreated (prodromal disease).

As drug development shifts toward these prodromal patients, likely with premium-priced biological therapies, the market will expand considerably. There are no drug treatments that can cure Alzheimer’s disease or any other common type of dementia.

  • There is a substantial opportunity for pharma companies to drive an increase in the wider Alzheimer’s market by improving diagnostic capabilities.
    • The number of drug candidates in development for Alzheimer’s is at its highest-ever level.
  • Despite the lack of success to date, biopharma companies continue to believe the potential rewards are worth the risk. As R&D in the field accelerates, therapies that treat not only symptoms of the disease but also slow its progression are expected to arrive much earlier.

The U.S. Food and Drug Administration (FDA) has approved two types of medications – cholinesterase inhibitors and memantine to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer’s disease.

  • Majority of innovative products for Alzheimer’s currently in clinical trials are based on the amyloid hypothesis where it is believed a fault with the processing of amyloid precursor protein (APP) in the brain leads to the production of a short fragment of APP known as beta-amyloid.
    • The current main focus of AD treatment is the inhibition of Aβ aggregation and the acceleration of Aβ clearance. Immunotherapies that target either Aβ or tau are being intensively investigated in Phase III trials, and large-scale Phase III trials of small-molecule BACE1 (β-secretase 1) inhibitors have also been initiated.

The global market for Alzheimer’s drugs report provides market size (revenue $million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global Alzheimer’s disease market segmented by drug class (product/brand) – cholinesterase inhibitors / acetylcholinesterase (AChE) inhibitors [Aricept (donepezil hydrochloride), Exelon / Prometax (rivastigmine tartrate), Razadyne / Reminyl / Nivalin (galantamine), Cognex (tacrine)], N-methyl-daspartate (NMDA) receptor antagonists [Ebixa / Namenda/ Axura / Akatinol / Memary (memantine)], pipeline analysis (phase III) – anti-amyloid agents [Aducanumab (BIIB037), BAN2401 (mAb158), Keppra (levetiracetam)], anti-amyloid, anti-inflammatory agents [ALZT-OP1 (cromolyn sodium), GV-971 (sodium oligomannate)], neurotransmitters [Abilify (aripiprazole, BMS-337039), AVP-786, Rexulti (brexpiprazole, PC 34712), Lumateperone (ITI-007)], vitamin E supplements (alpha-tocopherol), others (protein kinase inhibitors) [Masivet / Kinavet (masitinib mesylate, AB1010)] and by geography.

The global market for Alzheimer’s drugs research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North American region remains the dominant market for AD therapies, accounting for over 40% of the total sales, followed by Japan in market share.
    • The market predicted to grow at a double-digit growth, making it one of the fastest-growing therapeutic areas in the industry. This growth is anticipated to be driven by the introduction of several new disease-modifying agents.

The global Alzheimer’s disease market report also provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for Alzheimer’s drugs include AB Science, Avanir Pharmaceuticals, Inc., AZTherapies, Inc., Biogen, Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Concert Pharmaceuticals, Inc., Eisai Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., H. Lundbeck A/S, Hoffmann-La Roche AG, Intra-Cellular Therapies, Inc., Janssen Pharmaceuticals, Inc. (J&J), Merz Pharma GmbH & Co. KGaA, Neurimmune AG, Novartis AG, Ortho-McNeil Pharmaceutical, Inc (J&J), Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc. (Warner-Lambert), Sanochemia Pharmazeutika AG, Shanghai Green Valley Pharmaceuticals Co., Ltd., Shionogi, Inc., Takeda Pharmaceutical Co., Ltd., TauRx Therapeutics, Ltd., and UCB S.A.

  • Drug Class (Product/Brand)
    • Cholinesterase inhibitors / Acetylcholinesterase (AChE) Inhibitors
      • Aricept (donepezil hydrochloride)
      • Exelon / Prometax / SDZ ENA 713 (rivastigmine)
      • Razadyne / Reminyl / Nivalin (galantamine)
      • Cognex (tacrine)
    • N-Methyl-Daspartate (NMDA) Receptor Antagonist
      • Ebixa / Namenda/ Axura / Akatinol / Memary (memantine)
  • Pipeline Analysis (Phase III)
    • Anti-Amyloid Agents
      • Aducanumab (BIIB037)
      • BAN2401  (mAb158)
      • Keppra (levetiracetam)
    • Anti-Amyloid, Anti-Inflammatory Agents
      • ALZT-OP1 (cromolyn sodium)
      • GV-971 (sodium oligomannate)
    • Neurotransmitters
      • Abilify (aripiprazole, BMS-337039)
      • AVP-786
      • Rexulti (brexpiprazole, PC 34712)
      • Lumateperone (ITI-007)
    • Vitamin E Supplement
      • Alpha-Tocopherol
    • Others (Protein Kinase Inhibitors)
      • Masivet / Kinavet (masitinib mesylate, AB1010)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AB Science
    • Allergan plc (Forest Laboratories, Inc.)
    • Avanir Pharmaceuticals, Inc.
    • AZTherapies, Inc.
    • Biogen, Inc.
    • Bristol-Myers Squibb Company
    • Chugai Pharmaceutical Co., Ltd.
    • Concert Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • Hoffmann-La Roche AG
    • Intra-Cellular Therapies, Inc.
    • Janssen Pharmaceuticals, Inc. (J&J)
    • Merz Pharma GmbH & Co. KGaA
    • Neurimmune AG
    • Novartis AG
    • Ortho-McNeil Pharmaceutical, Inc (J&J)
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc. (Warner-Lambert)
    • Sanochemia Pharmazeutika AG
    • Shanghai Green Valley Pharmaceuticals Co., Ltd.
    • Shionogi, Inc.
    • Takeda Pharmaceutical Co., Ltd.
    • TauRx Therapeutics, Ltd.
    • UCB S.A.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]